IGF-1 (native / Mecasermin)
70-aa Insulin-like Growth Factor-1. Native form (mecasermin / Increlex) is FDA-approved for severe primary IGF-1 deficiency. Distinct from the IGF-1 LR3 analog: native IGF-1 binds IGFBPs in plasma (shorter half-life, more tightly regulated tissue exposure); LR3 evades binding-protein sequestration (longer half-life, broader off-target exposure).
How it clearsHalf cleared in ~5h. Most (~96%) gone by ~1d.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
Mecasermin (Increlex, Tercica) was FDA-approved 2005 for primary severe IGF-1 deficiency in pediatric short stature. Clinical evidence in the on-label indication is solid — measurable growth response, well-characterized side-effect profile (hypoglycemia, intracranial hypertension, lymphoid hypertrophy). Off-label use in adult body-comp + anti-aging cohorts is research-grey + carries the same hypoglycemia + theoretical cancer-cell mobility concerns as LR3. Most r/Peptides recomp protocols use LR3 not native because LR3 is cheaper grey-market and has longer half-life; native IGF-1 is the better-characterized form for clinical work.
Hypoglycemia risk is documented + non-trivial. Lymphoid-tissue hypertrophy (tonsils, adenoids, lymph nodes) reported in pediatric trials. Active or recent malignancy is an absolute contraindication. Adult body-comp use is off-label + requires endocrinologist supervision + IGF-1 / glucose bloodwork. Don't confuse with IGF-1 LR3 — they're different molecules with different pharmacology.
Upload your data to see how it relates to IGF-1.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- BModerate evidence
IGF-1 (native / Mecasermin) — primary mechanism: 70-aa insulin-like growth factor-1. native form (mecasermin / increlex) is fda-approved for severe primary igf-1 deficiency. distinct from the igf-1 lr3 analog: native igf-1 binds igfbps in plasma (shorter half-life, more tightly regulated tissue exposure); lr3 evades binding-protein sequestration (longer half-life, broader off-target exposure).
2 supporting referencesVerified 13d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
FDA approved as Increlex (mecasermin) for pediatric IGF-1 deficiency · adult use is off-label
Pre-filled with this compound's published dose range: Pediatric on-label: 0.04-0.12 mg/kg BID · adult off-label varies · twice daily, subcutaneous (on-label)
Draw volume is below 5 units — hard to measure accurately on most syringes. Consider adding more BAC water to dilute, or moving to a smaller syringe.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.